The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Higher rates of mortality seen among patients with systemic lupus erythematosus, with disparities by sex, race and ethnicity, and region.

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Data suggest incidence and prevalence of systemic lupus erythematosus (SLE) vary widely among regions, although the authors noted some regions have been studied more extensively than others. A new ...

Worldwide incidence and prevalence estimates of systemic lupus erythematosus (SLE) vary substantially and are influenced by ethnic and geographic differences, study design and environmental exposures ...